INTS has 36-month beta value of 3.92. Analysts have mixed views on the stock, with 1 analysts rating it as a “buy,” 2 as “overweight,” 2 as “hold,” and 0 as “sell.”
The public float for INTS is 14.19M, and currently, short sellers hold a 4.65% ratio of that float. The average trading volume of INTS on June 30, 2025 was 1.18M shares.
INTS) stock’s latest price update
Intensity Therapeutics Inc (NASDAQ: INTS) has experienced a decline in its stock price by -2.88 compared to its previous closing price of 0.32. However, the company has seen a gain of 4.30% in its stock price over the last five trading days. prnewswire.com reported 2025-06-30 that SHELTON, Conn., June 30, 2025 /PRNewswire/ — Intensity Therapeutics, Inc. (Nasdaq: INTS) (“Intensity” or “the Company”), a late-stage clinical biotechnology company focused on the discovery and development of proprietary, novel immune-based intratumoral cancer therapies designed to kill tumors and increase immune system recognition of cancers, announces that INT230-6 achieved complete responses in a murine models of Malignant Peripheral Nerve Sheath Tumor (“MPNST”).
INTS’s Market Performance
INTS’s stock has risen by 4.30% in the past week, with a monthly drop of -20.10% and a quarterly drop of -84.06%. The volatility ratio for the week is 15.02% while the volatility levels for the last 30 days are 21.39% for Intensity Therapeutics Inc The simple moving average for the past 20 days is -19.32% for INTS’s stock, with a -85.41% simple moving average for the past 200 days.
INTS Trading at -43.99% from the 50-Day Moving Average
After a stumble in the market that brought INTS to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -93.91% of loss for the given period.
Stock Fundamentals for INTS
The total capital return value is set at -34.94. Equity return is now at value -298.57, with -194.04 for asset returns.
Based on Intensity Therapeutics Inc (INTS), the company’s capital structure generated 0.28 points at debt to capital in total, while cash flow to debt ratio is standing at -98.04.
Currently, EBITDA for the company is -16.24 million with net debt to EBITDA at 0.05. The liquidity ratio also appears to be rather interesting for investors as it stands at 0.63.
Conclusion
To put it simply, Intensity Therapeutics Inc (INTS) has had a bad performance in recent times. Analysts have a mixed opinion on the stock, with some rating it as a “buy” and others as a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
